secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277523
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics Q3 net loss $13.3M; Phase 3 NEAT trial on track for Q1 2026 data
--------------------------------------------------------------------------------

- Cash, cash equivalents, and short-term investments of $26.3M; runway expected through Q2 2026.
- Phase 3 NEAT enrollment completed (105 participants); topline results expected first quarter 2026.
- iDSMB recommended study continue without modifications; 100% of patients chose open-label extension.
- Net loss $13.3M ($0.25/sh); R&D expenses $8.1M, G&A expenses $3.3M for Q3 2025.
- FDA Fast Track designation; NDA submission planned H2 2026 assuming positive study results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312525277523/0001193125-25-277523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312525277523/qncx-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer